A Phase I Study of CPX-351 in Combination with Busulfan and Fludarabine Conditioning and Allogeneic Stem Cell Transplantation in Adult Patients with Refractory Acute Leukemia-Reference-Cited by-同舟云学术

A Phase I Study of CPX-351 in Combination with Busulfan and Fludarabine Conditioning and Allogeneic Stem Cell Transplantation in Adult Patients with Refractory Acute Leukemia

Published:2013-07 Issue:7 Volume:19 Page:1040-1045
ISSN:1083-8791
Container-title:Biology of Blood and Marrow Transplantation
language:en
Short-container-title:Biology of Blood and Marrow Transplantation

Author:

Gergis Usama,Roboz Gail,Shore Tsiporah,Ritchie Ellen,Mayer Sebastian,Wissa Usama,McKenna Marshall,Christos Paul,Pearse Roger,Mark Tomer,Scandura Joseph,van Besien Koen,Feldman Eric

Publisher

Elsevier BV

Subject

Transplantation,Hematology

Reference25 articles.

1. Design and analysis of trials of salvage therapy in acute myelogenous leukemia;Estey;Cancer Chemother Pharmacol,1997

2. Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy;Ravandi;Blood,2010

3. Prognostic index for adult patients with acute myeloid leukemia in first relapse;Breems;J Clin Oncol,2005

4. A new leukemia prognostic scoring system for refractory/relapsed adult acute myelogeneous leukaemia patients: a GOELAMS study;Chevallier;Leukemia,2011

5. Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure;Duval;J Clin Oncol,2010

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A new sequential conditioning regimen based on CPX- 351/Vyxeos (“Vyx-Seq”) in patients with higher risk myelodysplastic syndromes;Leukemia Research;2023-12

2. The two-step approach to allogeneic hematopoietic stem cell transplantation;Frontiers in Immunology;2023-09-01

3. Current Status of CPX-351 Therapy in Acute Myeloid Leukemia and Myelodysplastic Syndrome;Clinical Lymphoma Myeloma and Leukemia;2022-08

4. Chemical Advances in Therapeutic Application of Exosomes and Liposomes;Current Medicinal Chemistry;2022-08

5. Haematologic malignancies with unfavourable gene mutations benefit from donor lymphocyte infusion with/without decitabine for prophylaxis of relapse after allogeneic HSCT: A pilot study;Cancer Medicine;2021-05